Intravenous infusion of 500 ml of 6% polyvinylpyrrolidone (PVP, average molecular weight 40,000) in isotonic saline solution daily for 2 days induced prompt and significant reductions in serum cholesterol and triglyceride concentrations in eight hyperlipidemic patients. Mean maximal decrements in serum cholesterol and triglyceride were 29% and 28% below control values, respectively, occurring 5 days after infusion of PVP. Mean values for hematocrit and total serum protein concentration were slightly decreased following PVP infusion, but there were no changes in percentage composition of serum proteins, blood sugar, serum sodium and potassium, body weight, and blood pressure. The hypolipidemic effect of PVP persisted beyond the period of plasma volume expansion, as demonstrated by measurement of the plasma volume isotopically and by long-term follow-up in five of the patients.
Additional Indexing Words: Plasma expander Cholesterol POLYVINYLPYRROLIDONE (PVP) is a plasma volume expander' developed during World War II by Hecht and Weese.2 Its hemodynamic effects, which result from plasma expansion, have been well investigated.3 Moreover, PVP is known to have other properties that seemingly are unrelated to expansion of plasma volume. PVP is capable of chemically binding dyes, bilirubin, insulin, penicillin, and other drugs.' When infused intravenously, it increases the aggregation of erythrocytes4 and their sedimentation rate5 but does not prolong the bleeding or clotting time.6 It decreases significantly platelet adhesiveness in human blood both in vivo and in vitro without altering the platelet count. 7 At high concentrations (about 40%), PVP (table 1) , ranging in age between 30 and 57 years. Six of them were females, three were slightly overweight, four were hypertensive, and three had grossly abnormal oral glucose tolerance tests (GTT), although the fasting blood sugar was within normal limits in all patients. At the time of study, all patients were clinically well and had normal endocrine, hepatic, and renal function, but they had "essential hyperlipidemia (hyperlipoproteinemia)." They all had hyperbeta-lipoproteinemia and, except patient G. C., hyper-prebeta-lipoproteinemia by paper electrophoresis of serum lipoproteins.12 Only patients with hyperlipidemia were investigated because the specific purpose of this study was to determine whether or not PVP decreased serum lipids in human subjects. In view of the previous finding that the hypolipidemic effect of PVP is more pronounced in hyperlipidemic than in normal rats, we reasoned that our results with PVP should be more clear-cut if the starting level of serum lipids were elevated. During the period of study, the patients maintained the diets they had been given as outpatients. Two of them (A. V. and J. G.) had been on diets containing about 30 calories per kilogram and composed of 20% protein, 40% carbohydrate (complex), and 40% fat, half-unsaturated. The remaining six patients had been on the same amount of calories, of which 20% was protein, 55% carbohydrate (simple and complex), and 25% fat, half-unsaturated.
PVP Infusion
On the fourth and fifth days of hospitalization, each patient received intravenously 2-hour infusions of 500 ml of 6% PVP (average molecular weight 40,000) in isotonic saline solution. Vital signs, checked every 15 minutes during the infusion, were unaltered by PVP. No side effects to the drug were noted. Analyses
Venous blood was always obtained after 12 to 16 hours of fasting. Hematocrit, blood sugar, and serum sodium and potassium were analyzed by standard laboratory procedures. Serum cholesterol and triglyceride were determined by the techniques of Connerty and co-workers, 13 and Van Handel and Zilversmit,14 respectively. Serum proteins were separated electrophoretically with cellulose acetate paper, and they were quantitated according to the method of Kremers and co-workers.'5 Plasma volume was measured 1 day before and 4 days after PVP by means of 5 ,uc of I'31-labeled human albumin, with blood samples obtained at the time of injection, 10, 20, and 30 minutes after injection of radioiodinated albumin for extrapolation to time of injection to indicate plasma volume.
Circulation, Volume XXXVIII, October 1968 is 6 days after the first PVP infusion (table  2) . After discharge from the hospital, followup studies were performed in five of the patients ( fig. 1 ). As noted, the concentrations of serum cholesterol in these patients remained below control values for several weeks after PVP.
PVP infusion decreased serum triglyceride concentration in six patients (no definite change in patients A.M. and E.M.), with a mean maximal reduction of about 28% below control values occurring on day 10 (table 3) ; all mean serum triglyceride values after the infusions of PVP were not significantly different. As with cholesterol, the reduction in serum triglyceride was similarly prolonged in the five follow-up patients ( fig. 2) .
Mean values of total serum protein fell about 10% below control values following PVP (table 4), but the percentage composition of serum protein fractions remained unaltered.
Finally, as shown in table 5, mean hematocrit fell from an average of 42.6% before infusion to a minimum of 37.2% after PVP, the difference being statistically significant (P < 0.05). On the other hand, mean plasma volumes determined on days 3 and 9 were not PVP significantly different. Also, there were no changes in FBS, Na, K, body weight, or BP.
Discussion
In hyperlipidemic human subjects, intravenous administration of PVP substantially diminishes serum cholesterol and triglyceride concentrations, which is in keeping with the data by others" in normal and hyperlipidemic nephrotic rats.
The mechanism by which PVP decreases serum lipids is not clear from this study. Theoretically, the following possibilities may be considered: (a) dilution due to plasma volume expansion, (b) increased removal of blood lipids, and (c) decreased release of lipoproteins into the circulation.
As to the first possibility, PVP is an osmotically active macromolecular substance that effectively increases plasma volume for several hours after infusion.' Blood constituents, therefore, will be diluted by PVP, and this may partly explain the immediate fall in concentrations of serum lipids and protein and hematocrit. It should be noted, however, that maximal per cent decrease in serum lipids was approximately three times that of serum protein and hematocrit. Also, despite the fact that 4 days after PVP the plasma volume was the same as control, serum lipids were still diminished. In fact, serum lipids remained below control values for several weeks in five follow-up patients. It would appear then that either enhanced removal or inhibited release of circulating lipids (or lipoproteins) or both play some role in the hypolipidemic effect of PVP. Allen and co-workers'1 found no increase in release of lipoprotein lipase by PVP in rats. They stated further, on the basis of a pilot experiment on the in vitro synthesis of lipoproteins by liver slices taken from nephrotic rats which had received PVP, that "there was no gross impairment of hepatic lipoprotein synthesis in these rats compared with untreated nephrotic controls....7" One is left with the possibilities that PVP may either interfere in some manner with the binding of serum lipids to their "protein-carriers," socalled apolipoproteins, or that it may interact with circulating lipoproteins forming large macromolecules that are cleared by the reticuloendothelial system, where PVP is known to be stored.' Thus, more studies are needed to elucidate the mechanism of action of PVP on serum lipids.
Finally, it should be emphasized that PVP is known to have side effects, and caution must be exercised when it is administered. Plasma volume expansion can produce heart failure and pulmonary edema in the elderly and in patients with pre-existing heart disease.' Unlike the dog, in which PVP causes anaphylactic reactions, human beings do not develop such reactions.' Of particular importance is tissue storage of PVP. Approximately two thirds of the PVP infused in man is excreted in the urine and small amounts in the stools, whereas the unexcreted portion is retained principally in the reticuloendothelial system for several weeks.'6' 17 Storage of PVP may lead to complications that appear to be dose-related."8 Significant complications, including pulmonary, renal, hepatic, intestinal, and wound complications, were noted when the dose of PVP exceeded 70 g. Our patients each received a total of 60 g of PVP without any untoward effects. But, in view of its side effects and the need for parenteral administration, it is doubtful that PVP will be practical as a long-term hypolipidemic agent. As mentioned recently, however, it may be Circulation, Volume Figure 3 Effects of combined therapy of plasma expanders, PVP and dextran, and cholestyramine on serum cholesterol in a patient with essential familial hypercholesterolemia. 19 of considerable value when used in combination with other drugs in the treatment of marked essential familial hypercholesterolemia. 19 Incidentally, the same thing may be said of dextran, which reportedly has a similar hypolipidemic effect.20 This point is illustrated in figure 3 , where both PVP and dextran were used to lower acutely the serum cholesterol in a patient with essential familial hypercholesterolemia, after which she was maintained on cholestyramine (Questran or Cuemid) except for a brief period 4 months later, when she could not obtain cholestyramine. At that time, she was given PVP before restarting cholestyramine.
